DJIA 15,179.85 109.67 0.73%
NASDAQ 3,452.13 28.57 0.83%
S&P 500 1,639.04 12.31 0.76%
market minute promo

MannKind Corp

NASDAQ: MNKD

+ Add to Portfolio

company name or ticker

The Coming Diabetes Wars

A major battle looms as leading insulin products lose patent protection. Here are the likely winners and losers of the coming diabetes wars.
5/23/2013 by DailyFinance

MannKind's Afrezza And The Oramed Threat

5/23/2013 by Seeking Alpha

Mid-Afternoon Market Update: MannKind Posts Huge Rally as Markets Plummet

5/22/2013 by Benzinga

Pricing A Highly Probable Takeover Of MannKind

5/22/2013 by Seeking Alpha

Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin

5/19/2013 by Seeking Alpha

5 of Last Week's Biggest Winners

These five companies posted double-digit gains this past week.
5/19/2013 by DailyFinance

U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying

5/18/2013 by Benzinga

1 Giant Leap for MannKind

MannKind shares have jumped over the moon lately. What's behind this giant leap?
5/18/2013 by DailyFinance

Why MannKind's Afrezza Will Succeed Where Pfizer Failed

5/18/2013 by Seeking Alpha

Benzinga's Top Initiations

5/15/2013 by Benzinga
See More Articles...